Novartis eyes first-line status for its radionucleotide therapy Lutathera
The Phase III trial of Luthathera as a first-line therapy showed improved progression-free survival in treating GEP-NETs.
The Phase III trial of Luthathera as a first-line therapy showed improved progression-free survival in treating GEP-NETs.
What's Your Reaction?
